|
 |
|
|||||||
|
|||||||||
© 2005 by the American Diabetes Association, Inc.
Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes |
Associations Between Liver Histology and Severity of the Metabolic Syndrome in Subjects With Nonalcoholic Fatty Liver Disease
1 Department of Gastroenterology, St. Vincent’s Hospital, Fitzroy, Australia
2 Department of Medicine, University of Melbourne, Parkville, Australia
3 Department of Pathology, St. Vincent’s Hospital, Fitzroy, Australia
Address correspondence and reprint requests to Dr. Marno C. Ryan, Department of Medicine, 4th Floor Clinical Sciences Building, St. Vincent’s Hospital, 41 Victoria Parade, Fitzroy 3065 Victoria, Australia. E-mail: marno.ryan@svhm.org.au
Abbreviations: ATP, Adult Treatment Panel • DEXA, dual-energy X-ray absorptiometry • HOMA, homeostasis model assessment • NAFLD, nonalcoholic fatty liver disease • NASH, nonalcoholic steatohepatitis
| The first 20% of the full text of this article appears below. |
 |
INTRODUCTION |
|---|
Nonalcoholic fatty liver disease (NAFLD) is associated with a histopathological picture resembling alcohol-induced liver injury occurring in subjects who consume insignificant amounts of alcohol. In NAFLD, steatosis alone is associated with good prognosis, whereas nonalcoholic steatohepatitis (NASH) can progress to fibrosis and cirrhosis in up to 30% of cases, potentially leading to liver failure and hepatocellular carcinoma. The prevalence of NAFLD and NASH in the U.S. is estimated at 10–20 and 2–3%, respectively (1,2,3).
The metabolic syndrome, as defined by Adult Treatment Panel (ATP) III criteria, incorporates features known to predict cardiovascular disease and type 2 diabetes (4). NAFLD has been demonstrated to be associated with features of the metabolic syndrome, including hyperglycemia (5,6), dyslipidemia (5,6), hypertension (7), and central obesity (7,8). In addition, insulin resistance, even without these other features, is almost universal in subjects with NAFLD (6). However, the factors specifically associated with hepatic inflammation, fibrosis, and thus liver disease progression are still being elucidated.
In this study of human subjects with NAFLD, we explored specific relationships between hepatic histology and markers of the metabolic syndrome.
|
RESEARCH DESIGN AND METHODS |
|---|
Forty-six subjects with NAFLD were recruited from clinics. The diagnosis was based on the histological presence of macrovesicular steatosis, with or without lobular inflammation, hepatocellular degeneration, or
|
RESULTS |
|---|
|
CONCLUSIONS |
|---|
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S A Harrison, D Oliver, H L Arnold, S Gogia, and B A Neuschwander-Tetri Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease Gut, October 1, 2008; 57(10): 1441 - 1447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M Browning, J. D Krebs, M. Siervo, R. M Hall, N. Finer, M. E. Allison, and S. A Jebb Inflammation is associated with liver function markers, independent of other metabolic risk factors in overweight women The British Journal of Diabetes & Vascular Disease, March 1, 2008; 8(2): 73 - 76. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Targher, L. Bertolini, F. Poli, S. Rodella, L. Scala, R. Tessari, L. Zenari, and G. Falezza Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients Diabetes, December 1, 2005; 54(12): 3541 - 3546. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |